Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin effects on biomarkers in colorectal cancer
NCT01632020Phase 2Terminated
- Sponsor
- University of Arkansas
- Start
- Aug 2012
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liquid metformin (Aspargo Labs) in colorectal cancer (CRC) (2 arms), sponsored by University of Arkansas. Primary endpoints: Proliferation Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy and Mucosal Apoptotic Status of CRC Tumor and Adjacent Normal Tissue Following Metformin Therapy. Started Aug 2012; status: terminated.
02
Drugs
liquid metformin (Aspargo Labs)
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01632020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01632020.